M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets
MS201924_0002
Phase 2 small_molecule active
Quick answer
M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets for Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active